- Home
- REKR vs MGNX Comparison
REKR vs MGNX Comparison
Compare REKR & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REKR
- MGNX
- Stock Information
- Founded
- REKR 2017
- MGNX 2000
- Country
- REKR United States
- MGNX United States
- Employees
- REKR N/A
- MGNX N/A
- Industry
- REKR Telecommunications Equipment
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- REKR Telecommunications
- MGNX Health Care
- Exchange
- REKR Nasdaq
- MGNX Nasdaq
- Market Cap
- REKR 115.1M
- MGNX 125.2M
- IPO Year
- REKR N/A
- MGNX 2013
- Fundamental
- Price
- REKR $0.84
- MGNX $1.22
- Analyst Decision
- REKR
- MGNX Hold
- Analyst Count
- REKR 0
- MGNX 10
- Target Price
- REKR N/A
- MGNX $6.83
- AVG Volume (30 Days)
- REKR 3.7M
- MGNX 764.1K
- Earning Date
- REKR 05-14-2025
- MGNX 05-08-2025
- Dividend Yield
- REKR N/A
- MGNX N/A
- EPS Growth
- REKR N/A
- MGNX N/A
- EPS
- REKR N/A
- MGNX N/A
- Revenue
- REKR $46,028,000.00
- MGNX $149,962,000.00
- Revenue This Year
- REKR $42.85
- MGNX N/A
- Revenue Next Year
- REKR $36.19
- MGNX $25.32
- P/E Ratio
- REKR N/A
- MGNX N/A
- Revenue Growth
- REKR 31.76
- MGNX 155.26
- 52 Week Low
- REKR $0.78
- MGNX $1.17
- 52 Week High
- REKR $2.67
- MGNX $19.54
- Technical
- Relative Strength Index (RSI)
- REKR 33.10
- MGNX 18.97
- Support Level
- REKR $0.79
- MGNX $1.89
- Resistance Level
- REKR $1.18
- MGNX $2.24
- Average True Range (ATR)
- REKR 0.09
- MGNX 0.16
- MACD
- REKR 0.00
- MGNX -0.07
- Stochastic Oscillator
- REKR 11.25
- MGNX 4.55
About REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which the majority of its revenue comes from the United States.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).